• 1
    Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 46971
  • 2
    Rhodes T, Girman CJ, Jaconsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40–79 years old. J Urol 1999; 161: 1174
  • 3
    Homma Y, Imago C, Takahahi S, Kawabe K, Aso Y. Urinary symptoms and urodynamics in a normal elderly population. Scand J Urol Nephrol (Suppl) 1994; 157: 27
  • 4
    Williams AM, Simon I, Landis PK et al. Prostates growth rate determined from MRI data: age-related longitudinal changes. J Androl 1999; 20: 474
  • 5
    Bosch JL, Bohnen AM, Groeneveld FP. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50–78 years: the Krimpen Study. Eur Urol 2004; 46: 7539
  • 6
    Roehrborn CG, McConnell JD, Lieber MM et al., for the PLESS Study Group. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 47380
  • 7
    McConnell JD, Roehrborn CG, Bautista OM et al., Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798
  • 8
    Marks LS, Roehrborn CG, Andriole GL. Prevention of Benign Prostatic Hyperplasia Disease. J Urol 2006; 176: 1299306
  • 9
    StataCorp. Stata Statistical Software: Release 8. College Station, TX: StataCorp LP, 2003
  • 10
    Andersen JT, Ekman P, Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995; 46: 6317
  • 11
    Bent S, Kane C, Shinohara K et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 55766
  • 12
    Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY, on behalf of the CUSP Investigators. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community-based study. Clin Ther 1995; 17: 95669
  • 13
    Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 2919
  • 14
    Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992; 327: 118591
  • 15
    Kirby RS, Roehrborn C, Boyle P et al., Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 11926
  • 16
    Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 5339
  • 17
    Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. The PROWESS Study Group. Urology 1998; 51: 67786
  • 18
    McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. The Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338: 6123
  • 19
    Nickel JC, Fradet Y, Boake RC et al., the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996; 155: 12519
  • 20
    Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47: 15968
  • 21
    Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, on behalf of the ARIA 3001, ARIA 3002 and ARIA 3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 43441
  • 22
    Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 73441
  • 23
    Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther 1997; 19: 24358
  • 24
    Emberton M, Hartung R, Matzkin H et al. Symptomatic progression under treatment and history of AUR are the strongest predictors for AUR in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005; 66: 31622
  • 25
    Roberts RO, Lieber MM, Jacobson DJ, Girman CJ, Jacobsen SJ. Limitations of using outcomes in the placebo arm of a clinical trial of benign prostatic hyperplasia to quantify those in the community. Mayo Clin Proc 2005; 80: 75964
  • 26
    Souverein PC, Van Riemsdijk MM, De La Rosette JJ, Opdam PC, Leufkens HG. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: a population-based cohort study in the Netherlands. Eur Urol 2004; 47: 50510